Regorafenib Patent Expiration
Regorafenib is Used for treating gastrointestinal stromal tumors (GIST) in patients, including those who have previously been treated with imatinib and those with resistance to a KIT tyrosine kinase inhibitor. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Regorafenib Patents
Given below is the list of patents protecting Regorafenib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Stivarga | US9957232 | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate | Jul 09, 2032 | Bayer Hlthcare |
| Stivarga | US9458107 | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate | Apr 08, 2031 | Bayer Hlthcare |
| Stivarga | US8637553 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | Feb 16, 2031 | Bayer Hlthcare |
| Stivarga | US8680124 | Treatment of cancers with acquired resistance to kit inhibitors | Jun 02, 2030 | Bayer Hlthcare |
| Stivarga | US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Regorafenib's patents.
Latest Legal Activities on Regorafenib's Patents
Given below is the list recent legal activities going on the following patents of Regorafenib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Mar, 2024 | US9458107 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2021 | US9957232 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Jul, 2021 | US8637553(Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Mar, 2020 | US9458107 |
| Patent Issue Date Used in PTA Calculation Critical | 01 May, 2018 | US9957232 |
| Recordation of Patent Grant Mailed Critical | 01 May, 2018 | US9957232 |
| Email Notification Critical | 12 Apr, 2018 | US9957232 |
| Issue Notification Mailed Critical | 11 Apr, 2018 | US9957232 |
| Pubs Case Remand to TC Critical | 27 Mar, 2018 | US9957232 |
| Printer Rush- No mailing | 27 Mar, 2018 | US9957232 |
Regorafenib's Family Patents
Explore Our Curated Drug Screens
Regorafenib Generic API Manufacturers
Only one generic application has been filed for Regorafenib.
Given below is the list of companies who have filed for Regorafenib generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS LABS FL
Actavis Laboratories Fl Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 1 generic for Regorafenib. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG | tablet | Prescription | ORAL | AB | Jan 13, 2025 |